Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | CNR1 | P21554 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12513696 | 0.81 | GAA (0.54) | GAAALDH1A1CNR1KDM4ESMN1; SMN2 | |
| SCHEMBL9410255 | 0.80 | ALDH1A1 (0.59) | GAAALDH1A1EPHX2HTTHTR4 | |
| SCHEMBL12513580 | 0.79 | GAA (0.52) | GAAALDH1A1CNR1KDM4ESMN1; SMN2 | |
| SCHEMBL485925 | 0.78 | ALDH1A1 (0.48) | ALDH1A1EPHX2HTR4HSD17B10NPSR1 | |
| SCHEMBL12438184 | 0.78 | GAA (0.51) | GAAALDH1A1CNR1KDM4ESMN1; SMN2 | |
| SCHEMBL8771387 | 0.77 | ALDH1A1 (0.61) | GAAALDH1A1EPHX2HTR4CYP2C19 | |
| SCHEMBL12438244 | 0.76 | GAA (0.49) | GAAALDH1A1CNR1KDM4ESMN1; SMN2 | |
| SCHEMBL11554175 | 0.75 | CYP2C19 (0.81) | ALDH1A1EPHX2HTTCYP2C19SMN1; SMN2 | |
| SCHEMBL14139915 | 0.75 | HRH3 (0.52) | GAA | |
| SCHEMBL14329888 | 0.74 | ALDH1A1 (0.94) | GAAALDH1A1EPHX2CNR1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100222319-A1 | NICOTINAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2010-09-02 | — | — | US | disclosed |
| EP-2205566-A2 | NICOTINAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | Sanofi-Aventis (FR) | 2010-07-14 | — | — | EP | disclosed |
| WO-2009074749-A2 | NICOTINAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2009-06-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222319-A1 | NICOTINAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | NNT, NAMPT, NQO1 | GAA 730/4885ALDH1A1 380/4885EPHX2 1700/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.